{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T16:46:11Z","timestamp":1784133971673,"version":"3.55.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009392","name":"Prince Sattam bin Abdulaziz University","doi-asserted-by":"publisher","award":["PSAU\/2025\/R\/1447"],"award-info":[{"award-number":["PSAU\/2025\/R\/1447"]}],"id":[{"id":"10.13039\/100009392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007446","name":"King Khalid University","doi-asserted-by":"publisher","award":["RGP2\/8\/45"],"award-info":[{"award-number":["RGP2\/8\/45"]}],"id":[{"id":"10.13039\/501100007446","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.cpcardiol.2025.103170","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T16:01:03Z","timestamp":1756915263000},"page":"103170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["The triadic relationship between nonalcoholic fatty liver disease, type 2 diabetes, and cardiovascular disease: From molecular mechanisms to clinical management"],"prefix":"10.1016","volume":"50","author":[{"given":"Yuxi","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Alissa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Ezzat","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin A.","family":"Al-Doaiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naif","family":"Asiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasser","family":"Assiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahid Ullah","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munir Ullah","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpcardiol.2025.103170_bib0001","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrgastro.2013.41","article-title":"Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis","volume":"10","author":"Anstee","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cpcardiol.2025.103170_bib0002","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.jep.2016.07.024","article-title":"The effect of Liuwei Dihuang decoction on PI3K\/Akt signaling pathway in liver of type 2 diabetes mellitus (T2DM) rats with insulin resistance","volume":"192","author":"Dai","year":"2016","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.cpcardiol.2025.103170_bib0003","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.cpcardiol.2025.103170_bib0004","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2014meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.cpcardiol.2025.103170_bib0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cpcardiol.2025.103170_bib0006","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0173499","article-title":"Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States","volume":"12","author":"Le","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.cpcardiol.2025.103170_bib0007","doi-asserted-by":"crossref","first-page":"5431","DOI":"10.2147\/DDDT.S282206","article-title":"Xanthohumol inhibits TGF-\u03b21-induced cardiac fibroblasts activation via mediating PTEN\/Akt\/mTOR signaling pathway","volume":"14","author":"Jiang","year":"2020","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.cpcardiol.2025.103170_bib0008","doi-asserted-by":"crossref","first-page":"1182803","DOI":"10.3389\/fphar.2023.1182803","article-title":"Integrated transcriptome and metabolome analysis to investigate the mechanism of intranasal insulin treatment in a rat model of vascular dementia","volume":"14","author":"Tang","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.cpcardiol.2025.103170_bib0009","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1053\/j.gastro.2014.11.039","article-title":"Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States","volume":"148","author":"Wong","year":"2015","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103170_bib62","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s11033-025-10249-0","article-title":"An insight on the additive impact of type 2 diabetes mellitus and nonalcoholic fatty liver disease on cardiovascular consequences","volume":"52","author":"Bhardwaj","year":"2025","journal-title":"Molecular Biology Reports"},{"key":"10.1016\/j.cpcardiol.2025.103170_bib0010","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/gutjnl-2017-313884","article-title":"Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases","volume":"66","author":"Adams","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.cpcardiol.2025.103170_bib0011","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1161\/ATVBAHA.107.147538","article-title":"Fatty liver: a novel component of the metabolic syndrome","volume":"28","author":"Kotronen","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cpcardiol.2025.103170_bib0012","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.jacc.2015.06.1328","article-title":"The cardiometabolic health alliance: working toward a new care model for the metabolic syndrome","volume":"66","author":"Sperling","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2025.103170_bib0013","article-title":"Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: a systematic review and meta-analysis","volume":"6","author":"Wu","year":"2016","journal-title":"Sci Rep"},{"issue":"8","key":"10.1016\/j.cpcardiol.2025.103170_bib63","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.jacc.2018.11.050","article-title":"Nonalcoholic fatty liver disease and the heart: JACC state-of-the-art review","volume":"73","author":"tahl","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2025.103170_bib0014","doi-asserted-by":"crossref","first-page":"154887","DOI":"10.1016\/j.phymed.2023.154887","article-title":"Quercetin: A promising therapy for diabetic encephalopathy through inhibition of hippocampal ferroptosis","volume":"126","author":"Cheng","year":"2024","journal-title":"Phytomedicine"},{"key":"10.1016\/j.cpcardiol.2025.103170_bib0015","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1093\/eurheartj\/ehv134","article-title":"Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes","volume":"36","author":"Seferovi\u0107","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2025.103170_bib0016","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCRESAHA.117.311586","article-title":"Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity","volume":"122","author":"Jia","year":"2018","journal-title":"Circ Res"},{"issue":"20","key":"10.1016\/j.cpcardiol.2025.103170_bib0017","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.2174\/0113816128302667240422110226","article-title":"The regulation of selenoproteins in diabetes: A new way to treat diabetes","volume":"30","author":"Liang","year":"2024","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.cpcardiol.2025.103170_bib0018","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.amjcard.2015.02.005","article-title":"Relation of reduced preclinical left ventricular diastolic function and cardiac remodeling in overweight youth to insulin resistance and inflammation","volume":"115","author":"Dahiya","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cpcardiol.2025.103170_bib0019","doi-asserted-by":"crossref","first-page":"108801","DOI":"10.1016\/j.pharmthera.2025.108801","article-title":"From physiology to pathology: Emerging roles of GPER in cardiovascular disease","volume":"267","author":"Wang","year":"2025","journal-title":"Pharmacol & Ther"},{"issue":"5","key":"10.1016\/j.cpcardiol.2025.103170_bib64","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1111\/dom.16242","article-title":"Mechanisms of diabetic cardiomyopathy: Focus on inflammation","volume":"27","author":"Bellemare","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.cpcardiol.2025.103170_bib0020","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2023.2195991","article-title":"Design, synthesis and biological evaluation of novel histone deacetylase (HDAC) inhibitors derived from \u03b2-elemene scaffold","volume":"38","author":"Gao","year":"2023","journal-title":"J Enzyme Inhib Med Chem"},{"key":"10.1016\/j.cpcardiol.2025.103170_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.cpcardiol.2025.103170_bib0022","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.cld.2023.01.019","article-title":"Hepatic outcomes of nonalcoholic fatty liver disease including cirrhosis and hepatocellular carcinoma","volume":"27","author":"Alqahtani","year":"2023","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.cpcardiol.2025.103170_bib0023","doi-asserted-by":"crossref","first-page":"436","DOI":"10.3350\/cmh.2024.0109","article-title":"Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis","volume":"30","author":"Crane","year":"2024","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.cpcardiol.2025.103170_bib0024","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.2337\/dci23-0027","article-title":"Hunting for progressive NAFLD in type 2 diabetes: do not trust liver enzymes!","volume":"46","author":"Scoditti","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cpcardiol.2025.103170_bib0025","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jhep.2022.11.010","article-title":"A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes","volume":"78","author":"Ajmera","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.cpcardiol.2025.103170_bib0026","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1002\/hep.31806","article-title":"Glycemic control predicts severity of hepatocyte ballooning and hepatic fibrosis in nonalcoholic fatty liver disease","volume":"74","author":"Alexopoulos","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.cpcardiol.2025.103170_bib0027","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S2468-1253(23)00157-7","article-title":"Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis","volume":"8","author":"Huang","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cpcardiol.2025.103170_bib0028","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/jdi.13756","article-title":"Non-alcoholic fatty liver disease and type 2 diabetes: an update","volume":"13","author":"Lee","year":"2022","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.cpcardiol.2025.103170_bib0036","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.3748\/wjg.v20.i7.1724","article-title":"Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease","volume":"20","author":"Ballestri","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cpcardiol.2025.103170_bib0029","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hep.26510","article-title":"Prothrombotic factors in histologically proven nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"59","author":"Verrijken","year":"2014","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103170_bib0030","first-page":"1","article-title":"Type 2 diabetes mellitus and the gut microbiota: Charting new territory for sodium-glucose co-transporter 2 inhibitors","volume":"8","author":"Natalia","year":"2024","journal-title":"Eurasian J Med Oncol"},{"key":"10.1016\/j.cpcardiol.2025.103170_bib0031","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/hep.25739","article-title":"Nonalcoholic steatohepatitis versus steatosis: adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein metabolism","volume":"56","author":"Musso","year":"2012","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cpcardiol.2025.103170_bib0032","doi-asserted-by":"crossref","first-page":"278","DOI":"10.56434\/j.arch.esp.urol.20247703.37","article-title":"Risk factors for urinary tract infection in elderly patients with type 2 diabetes: A retrospective cohort study","volume":"77","author":"Ni","year":"2024","journal-title":"Arch Esp Urol"},{"key":"10.1016\/j.cpcardiol.2025.103170_bib0033","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1161\/ATVBAHA.111.228262","article-title":"Hepatic steatosis, obesity, and the metabolic syndrome are independently and additively associated with increased systemic inflammation","volume":"31","author":"Ndumele","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cpcardiol.2025.103170_bib0034","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jhep.2009.06.023","article-title":"Thrombotic risk factors and liver histologic lesions in non-alcoholic fatty liver disease","volume":"51","author":"Papatheodoridis","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.cpcardiol.2025.103170_bib0035","doi-asserted-by":"crossref","first-page":"5834","DOI":"10.3748\/wjg.v11.i37.5834","article-title":"Association between thrombotic risk factors and extent of fibrosis in patients with non-alcoholic fatty liver diseases","volume":"11","author":"Assy","year":"2005","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cpcardiol.2025.103170_bib0037","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2025.103170_bib0038","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2337\/dc19-1113","article-title":"Economic and clinical burden of nonalcoholic steatohepatitis in patients with type 2 diabetes in the US","volume":"43","author":"Younossi","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cpcardiol.2025.103170_bib0039","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000000913","article-title":"Epidemiology, screening, and Co-management of type 2 diabetes mellitus and metabolic-dysfunction associated steatotic liver disease","author":"Qi","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.cpcardiol.2025.103170_bib0040","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/dme.13565","volume":"35","author":"Sberna","year":"2018","journal-title":"Diabet Med"},{"key":"10.1016\/j.cpcardiol.2025.103170_bib0041","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.joim.2020.03.001","article-title":"Guidelines for diagnosis and treatment of hepatic fibrosis with integrated traditional Chinese and Western medicine (2019 edition)","volume":"18","author":"Xu","year":"2020","journal-title":"J Integr Med"},{"key":"10.1016\/j.cpcardiol.2025.103170_bib0042","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jhep.2024.03.023","article-title":"Prospective head-to-head comparison of non-invasive scores for diagnosis of fibrotic MASH in patients with type 2 diabetes","volume":"81","author":"Castera","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.cpcardiol.2025.103170_bib0043","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-019-0806-4","article-title":"Targeting the glucagon receptor improves cardiac function and enhances insulin sensitivity following a myocardial infarction","volume":"18","author":"Karwi","year":"2019","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"10.1016\/j.cpcardiol.2025.103170_bib0044","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3923\/ijp.2024.672.681","article-title":"Comparing efficacy and safety of glucagon-like peptide 1 (GLP-1) agonist versus sodium-glucose cotransporter 2 (SGLT-2) inhibitors in chinese patients with type 2 diabetes mellitus: A preliminary study","volume":"20","author":"Wei","year":"2024","journal-title":"Int J Pharmacol"},{"key":"10.1016\/j.cpcardiol.2025.103170_bib0045","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.jacc.2009.04.074","article-title":"Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging","volume":"54","author":"Rijzewijk","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2025.103170_bib0046","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1042\/BCJ20180617","article-title":"Allosteric, transcriptional and post-translational control of mitochondrial energy metabolism","volume":"476","author":"Karwi","year":"2019","journal-title":"Biochem J"},{"key":"10.1016\/j.cpcardiol.2025.103170_bib0047","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.3390\/cells10113259","article-title":"The contribution of cardiac fatty acid oxidation to diabetic cardiomyopathy severity","volume":"10","author":"Karwi","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.cpcardiol.2025.103170_bib0048","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1111\/j.1464-5491.1991.tb02168.x","article-title":"Myocardial metabolism in type 1 diabetic patients without coronary artery disease","volume":"8","author":"Doria","year":"1991","journal-title":"Diabet Med"},{"key":"10.1016\/j.cpcardiol.2025.103170_bib0049","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jacc.2005.09.030","article-title":"Increased myocardial fatty acid metabolism in patients with type 1 diabetes mellitus","volume":"47","author":"Herrero","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2025.103170_bib0050","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/iub.1063","article-title":"Metformin reverses hexokinase and phosphofructokinase downregulation and intracellular distribution in the heart of diabetic mice","volume":"64","author":"Da Silva","year":"2012","journal-title":"IUBMB"},{"issue":"186","key":"10.1016\/j.cpcardiol.2025.103170_bib0051","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.24976\/Discov.Med.202436186.129","article-title":"Effects of IL-6R expression on IL-6\/STAT3\/HIF-1\u03b1 signaling pathway in a mouse model of parkinson\u2019s disease with type 2 diabetes Co-morbidity","volume":"36","author":"Hu","year":"2024","journal-title":"Discov Med"},{"key":"10.1016\/j.cpcardiol.2025.103170_bib0052","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1161\/CIRCRESAHA.119.316260","article-title":"Noninvasive in vivo assessment of cardiac metabolism in the healthy and diabetic human heart using hyperpolarized 13C MRI","volume":"126","author":"Rider","year":"2020","journal-title":"Circ Res"},{"key":"10.1016\/j.cpcardiol.2025.103170_bib0053","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/TP.0000000000003867","article-title":"Management of diabetes in candidates for liver transplantation and in transplant recipients","volume":"106","author":"Brodosi","year":"2022","journal-title":"Transplantation"},{"key":"10.1016\/j.cpcardiol.2025.103170_bib0054","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1007\/s00394-020-02346-6","article-title":"An updated systematic review and meta-analysis on adherence to mediterranean diet and risk of cancer","volume":"60","author":"Morze","year":"2021","journal-title":"Eur J Nutr"},{"key":"10.1016\/j.cpcardiol.2025.103170_bib0055","first-page":"178","article-title":"The effect of aerobic exercise on metabolic parameters of patients with non-alcoholic fatty liver disease: systematic review and meta-analysis","volume":"63","author":"Ghaffari","year":"2022","journal-title":"J Sports Med Phys Fit"},{"key":"10.1016\/j.cpcardiol.2025.103170_bib0056","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1007\/s00535-024-02122-x","article-title":"Effects of luseogliflozin on suspected MASLD in patients with diabetes: a pooled meta-analysis of phase III clinical trials","volume":"59","author":"Kawaguchi","year":"2024","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.cpcardiol.2025.103170_bib0057","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2025.103170_bib0058","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1111\/liv.15656","article-title":"Protective effects of statins on the incidence of NAFLD\u2013related decompensated cirrhosis in T2DM","volume":"43","author":"Wu","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.cpcardiol.2025.103170_bib0059","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154752","article-title":"Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes","volume":"121","author":"Ciardullo","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.cpcardiol.2025.103170_bib0060","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.3390\/life12081189","article-title":"New insights into non-alcoholic fatty liver disease and coronary artery disease: the liver-heart axis","volume":"12","author":"Cazac","year":"2022","journal-title":"Life"},{"key":"10.1016\/j.cpcardiol.2025.103170_bib0061","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ijcard.2016.11.247","article-title":"Sirtuin 1 protects the aging heart from contractile dysfunction mediated through the inhibition of endoplasmic reticulum stress-mediated apoptosis in cardiac-specific Sirtuin 1 knockout mouse model","volume":"228","author":"Hsu","year":"2017","journal-title":"Int J Cardiol"},{"issue":"19","key":"10.1016\/j.cpcardiol.2025.103170_bib65","doi-asserted-by":"crossref","first-page":"10595","DOI":"10.3390\/ijms251910595","article-title":"Non-alcoholic fatty liver disease and coronary artery disease: A bidirectional association based on endothelial dysfunction","volume":"25","author":"Ktenopoulos","year":"2024","journal-title":"Int J Mol Sci"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280625001902?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280625001902?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T05:47:15Z","timestamp":1758865635000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280625001902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":65,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0146280625001902"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2025.103170","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The triadic relationship between nonalcoholic fatty liver disease, type 2 diabetes, and cardiovascular disease: From molecular mechanisms to clinical management","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2025.103170","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103170"}}